Advances in Gene Editing and Gene Silencing - Part 2 Header


Cambridge Healthtech Institute’s 13th annual two-part conference on Advances in Gene Editing and Gene Silencing will cover the latest in the use of CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)/Cas9-based gene editing and RNA interference (RNAi) for use in drug discovery and for developing novel drug therapies.

Part 2 will cover the latest in the use of CRISPR/Cas9 and RNAi for functional screening. It will cover everything from assay design to data analysis when conducting low and high throughput screens and generating cellular models, both in vitro and in vivo, using CRISPR/Cas9, siRNA (small interfering RNA), and shRNA (short hairpin RNA), in a way that will evoke thought-provoking discussions and sharing of best practices. Screening experts from pharma/biotech as well as from academic and government labs will share their experiences leveraging the utility of these diverse screening platforms for a wide range of applications.

Preliminary Agenda


INTERPRETING DATA FROM CRISPR/RNAi SCREENS

Differences Between CRISPR/RNAi Necessitate Re-Thinking Analysis Algorithms

Eugen Buehler, Ph.D., Group Leader, Informatics, National Center for Advancing Translational Sciences, National Institutes of Health

Extracting Novel Insight from Genome-Scale Genetic Screens Through Integrated Iterative Analysis

Iain Fraser, Ph.D., Investigator, Laboratory of Systems Biology, National Institute of Allergy and Infectious Diseases, National Institutes of Health

Towards Combinatorial Drug Discovery: Mining Heterogenous Phenotypes from Large Scale RNAi/Drug Perturbations

Arvind Rao, Ph.D., Assistant Professor, Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center

PANEL DISCUSSION: Strategies to Interpret and Prioritize Data from CRISPR and RNAi Screens

Moderator: Eugen Buehler, Ph.D., Group Leader, Informatics, National Center for Advancing Translational Sciences, National Institutes of Health


USING CRISPR/RNAi FOR TARGET DISCOVERY & PATHWAY ANALYSIS

CRISPR Libraries for Functional Genomics: Optimizing On-Target Activity and Avoiding Off-Target Effects

John Doench, Ph.D., Associate Director, Genetic Perturbation Platform, Broad Institute of Harvard and MIT

The Right Tool for the Job: Complementary Uses of RNAi and CRISPR in Drug Discovery

Jonathan Preall, Ph.D., Senior Scientist, Oncology Target Discovery Group, Pfizer, Inc.


CRISPR-BASED FUNCTIONAL SCREENING FOR ONCOLOGY

Large Scale CRIPSR Screens for Discovery of Genotype Specific Combination Therapies

Roderick Beijersbergen, Ph.D., Group Leader, Netherlands Cancer Institute and Head, NKI Robotics and Screening Center

Immune Checkpoint Discovery Using RNAi Screens in Solid Tumors

Tillmann Michels, Head of Research Group, Immune Checkpoint Inhibitors, Department of Interventional Immunology, Regensburg Center for Interventional Immunology; Member, Department of Translational Immunology, German Cancer Research Center

CRISPR Mutagenesis Approach for Cancer Drug Target Identification

Junwei Shi, Ph.D., Assistant Professor, Department of Cancer Biology, University of Pennsylvania School of Medicine

Fas-Mediated Apoptosis Overcomes Resistance to Kras-Silencing in Lung Cancer Cells

Haiwei Mou, Ph.D., Postdoctoral Fellow, Laboratory of Dr. Wen Xue, RNA Therapeutics Institute and Program in Molecular Medicine, University of Massachusetts Medical School

Applying Functional Genomics in Mouse Models of Human Cancer

Yejing Ge, Ph.D., Postdoctoral Fellow, Laboratory of Dr. Elaine Fuchs, Department of Mammalian Cell Biology and Development, Rockefeller University




For questions or suggestions about the meeting, please contact:
Tanuja Koppal, Ph.D.
Conference Director
Cambridge Healthtech Institute
E: tkoppal@healthtech.com

For sponsorship and exhibit sales information including sponsored podium presentations, contact:
Jon Stroup
Senior Manager, Business Development
Cambridge Healthtech Institute
T: (+1) 781-972-5483
E: jstroup@healthtech.com